Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase 2 Clinical Trial-Dehydroepiandrosterone in Monoclonal Gammopathy-261065125
Mayo Clinic, Rochester, Rochester, MN, United States
Search grants from Mayo Clinic, Rochester
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Preclinical Imaging of Adolescent Cannabidiol on Brain Structure and Functional Connectivity
Research Center in Oral Biology
US-India Planning Visit: International Cooperative Program on the Producation of Biodegradable Polymers from Low-Cost Substrates
U.S-FSU Cooperative Science: Partial Funding of the 2nd USA-FSU (formerly USSR) Seminar on Ferroelectrics, St. Petersburg, Russia, June 22-26, 1992
US-Poland Research on Nuclear Structure at High Spin (Physics)
Recently added grants:
Patient Specific Tissue Engineered Vascular Graft Creation Using 3D Printing Technology
Care Coordination for High-Risk Patients with Multiple Chronic Conditions
Direct quantitation of the circulating Mtb-peptidome for pediatric TB management
SPAK inhibitor ZT-1a for ischemic stroke therapy
Defining high- and low-risk APOE 4 haplotypes for Alzheimers disease
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN065125-002
Application #
7191414
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2005
Total Cost
Indirect Cost
Institution
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Related projects
NIH 2005
N01 CN
Phase 2 Clinical Trial-Dehydroepiandrosterone in Monoclonal Gammopathy-261065125
/ Mayo Clinic, Rochester
NIH 1996
N01 CN
Phase II Clinical Trial Dehydroepiandrosterone
Lust, John Anthony / Mayo Clinic, Rochester
Comments
Be the first to comment on this grant